Skip to main content
SLAS2024 Main banner
Sartorius Ad
Back

Andrew D. Napper, PhD (he/him/his)

Bristol Myers Squibb, New Jersey, United States

Dr. Andrew Napper is Executive Director, Head of Automation and Assay technologies at Bristol Myers Squibb in Princeton, NJ. He studied at the University of Oxford and Penn State University before working in the Boston area for Genzyme, Enanta, ArQule, and Elixir Pharmaceuticals. While at Elixir, he played a leading role in the discovery of selisistat (EX-527), which was licensed to Siena Biotech and progressed to Phase II clinical trials as a treatment for Huntington’s disease. In 2005, he joined the University of Pennsylvania to direct one of the labs in the Molecular Libraries Screening Center Network. Dr. Napper joined Nemours in 2009 to establish a lab focused on the discovery of targeted therapies for rare pediatric diseases. After eight years at Nemours, he joined FLX Bio in the San Francisco Bay Area for one year before moving to Evotec as Vice President of Discovery Sciences and Princeton Site Head. From Evotec he joined BMS in March 2021. Dr. Napper was co-chair of the SLAS 2020 International Conference, and currently he serves as co-chair of the Screen Design and Assay Technology Special Interest Group and a member of the SLAS Awards and Grants Committee.

Disclosure information not submitted.

Presentation(s):